T-AK细胞在体外和裸鼠体内抗人膀胱癌细胞株(Fen)的实验研究

用可溶性肿瘤抗原和抗ＣＤ３ 单克隆抗体共同刺激外周单个核细胞（ＰＢＭＣ）产生ＣＤ＋８ Ｔ 细胞为主的杀瘤细胞，称为Ｔ－ ＡＫ 细胞。与ＬＡＫ细胞、ＣＤ３ － ＡＫ 细胞比较，Ｔ－ ＡＫ细胞扩增快、低依赖ＩＬ－ ２，培养１４ 天细胞数扩增２４ 倍，比ＣＤ３ － ＡＫ细胞高８ 倍，比ＬＡＫ细胞高１５ 倍，并能维持生长２１ 天。Ｔ－ ＡＫ细胞中含ＣＤ＋３ ８９％ ，ＣＤ＋４ ２１ ％ ，ＣＤ＋８ ９５％ ，ＣＤ＋１６ ２２％ ，ＣＤ＋２５ ４１％ ，ＣＤ＋５６ ４７ ％ ，ＣＤ＋３８ ９０ ％ ，它们是ＣＤ＋８ Ｔ细胞为主的异质性细胞群。体外实验结果表明，Ｔ－ ＡＫ细胞对Ｆｅｎ 的明显的杀伤作用，与ＬＡＫ、ＣＤ３ － ＡＫ细胞比较，差异有高度显著性（ Ｐ＜ ０．００１） 。裸鼠体内试验结果显示，对照组及ＬＡＫ组全部、ＣＤ３ － ＡＫ 组１ 只裸鼠长出瘤结节，而Ｔ－ ＡＫ组无一例长出瘤结节且生存期明显长

Laboratory study on the resistance of T-AK cells to Fens in vitro and in vivo naked mice

The irritation of PBMC by STA and monoclonal antibodies to CD 3 couldproduce a kind of killer tumor T-cells, known as T-AK cells. With comparison to LAK cells and CD 3-AK cells, T-AK cells had the advantages of rapid amplifying and low independence on IL-2. The amount of cells increased by 24 times after being cultured for 14 days, 8 times than that of CD 3-AK cells. and 15 times than LAK cells. The cells could keep alive for 21 days. T-AK cells contains 89%CD + 3, 21%CD + 4, 95%CD + 8, 22%CD + 16 , 41%CD + 25 , 47%CD + 56 and 90%CD + 38 . CD + 8 T-cells made up the greater part of these heterogeneity cells. The study results in vitro showed that T-AK cells had stronger ability of killing Fens, the statistical difference was markedly (P<0.001), with comparison to LAK and CD 3-AK cells. The study results in vivo naked Balb/c mice, aged 6 weeks, showed that all mice in the control group and LAK group , one in the CD 3-AK group grew tumor nodes. None of the mice in the T-AK group grew tumor nodes and their survival period was obviously long.